哌美克隆 | 534-84-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 哌美克隆
• 中文别名: 必美克酮
• 英文名称: 2-piperidin-1-ylmethyl-cyclohexanone
• 英文别名: 2-Piperidinomethyl-cyclohexanon；2-Piperidinomethyl-cyclohexanon-(1)；Pimeclone；2-(piperidin-1-ylmethyl)cyclohexan-1-one
• CAS: 534-84-9
• 化学式: C₁₂H₂₁NO
• mdl: MFCD00625530
• 分子量: 195.305
• InChiKey: PRFPQYGTPKDLHJ-UHFFFAOYSA-N

物化性质

• 熔点：
  <25 °C
• 沸点：
  bp14 118-120°; bp6 124°
• 密度：
  0.9628 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.916
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  哌美克隆 在 溶剂黄146 作用下， 以 苯 为溶剂， 生成 6,6-di(β-cyanoethyl)-2-piperidinomethylenecyclohexanone
  参考文献：
  名称：

  Dyusenova, Z. I.; Erzhanov, K. B.; Polatbekov, N. P., Journal of Organic Chemistry USSR (English Translation), 1983, p. 1112 - 1115

  摘要：

  DOI：
• 作为产物：
  描述：

  亚甲基环己烷 、 alkaline earth salt of/the/ methylsulfuric acid 在 臭氧 作用下， 以 正戊烷 为溶剂， 生成 哌美克隆
  参考文献：
  名称：

  The reactions of the ozonides with secondary amines: An efficient and novel way to prepare tertiary amine from mono- and 1,1-di-substituted alkenes via corresponding ozonides

  摘要：

  DOI：

  10.1016/s0040-4039(00)73982-7

文献信息

• A Novel Method for Biomimetic Synthesis of Mannich Bases
  作者：Yuan Guo、Jing An、Zhenhuan Lu、Mengjiao Peng

  DOI：10.1002/cjoc.201100628

  日期：2012.7

  reaction has become an important tool for the synthesis of new compounds. Mannich bases can be either directly employed or used as intermediates. In this work, the one‐carbon unit transfer reaction of tetrahydrofolate coenzyme was initiated. 1,3‐Dimethylimidazolidine as a new tetrahydrofolate coenzyme model at formaldehyde oxidation level was used to react with ketone having active hydrogen atoms and amine

  自从对Mannich进行早期研究以来，Mannich反应已成为合成新化合物的重要工具。曼尼希碱可以直接使用或用作中间体。在这项工作中，开始了四氢叶酸辅酶的单碳单位转移反应。1,3-二甲基咪唑烷作为甲醛氧化水平下的新型四氢叶酸辅酶模型，用于与具有活性氢原子的酮和胺反应，通过隐蔽的曼尼希反应以良好的收率得到相应的曼尼希碱。提供了一种用于仿生合成各种曼尼希碱的新颖方法。
• METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS
  申请人：TUFTS MEDICAL CENTER

  公开号：US20160052982A1

  公开（公告）日：2016-02-25

  The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

  本申请提供了制备可溶性脂质化配体药剂的方法，包括配体实体和脂质实体，并在某些实施例中提供了这些组分的相关参数，从而使得能够适当选择组分来组装出针对任何感兴趣的靶点的活性药剂。
• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• The mechanistic study and synthetic applications of the base treatment in the ozonolytic reactions
  作者：Yung-Son Hon、Sheng-Wun Lin、Ling Lu、Yao-Jung Chen

  DOI：10.1016/0040-4020(95)98699-i

  日期：1995.4

  E1cb mechanism is the overwhelming process in the reaction of bases and ozonides. As a quenching agent in the ozonolysis of a variety of alkenes, the reactions involving triethylamine often gave better yields and proceeded faster than those involving methyl sulfide. On the other hand, in the presence of 4 Å molecular sieves, the secondary amines reacted with mono- and 1,1-di-substituted ozonides to afford

  E1cb机制是碱和臭氧化物反应中的压倒性过程。作为各种烯烃的臭氧分解反应的淬灭剂，涉及三乙胺的反应通常比涉及甲基硫醚的反应收率更高，并且进行速度更快。另一方面，在4Å分子筛的存在下，仲胺与单和1,1-二取代的臭氧化物反应，以高收率提供还原性胺化产物。反应混合物中甲酸铵的形成也支持了臭氧化物与胺反应中的E1cb机理。